 In the United States, half of men with prostate cancer harbor the androgen-regulated gene fusion TMPRSS2:ERG.     ///    We hypothesized that men with TMPRSS2:ERG positive tumors are more responsive to androgen deprivation therapy (ADT).     ///    "Our results, combined with those from earlier studies, provide suggestive evidence that men with TMPRSS2:ERG positive tumors may have longer prostate cancer survival after ADT. "